Compare Sanofi SA (SNY) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Walmart Stores Inc — how do they compare? Sanofi SA trades at $43.91 (market cap $104.30B), while Walmart Stores Inc trades at $115.96 (market cap $923.22B). The key difference: Walmart Stores Inc is far larger — about 8.9× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| SNY | WMT | |
|---|---|---|
Market Cap | $104.30B | $923.22B |
Sector | Health | Consumer Staples |
52-Week High | $52.34 | $134.20 |
52-Week Low | $41.33 | $96.05 |
Enterprise Value | $124.19B | $986.67B |
Dividend Yield | 5.53% | 0.85% |
Volume | — | 5,675,288 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.78, up 0.51% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales outlook. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%. Key growth driver Dupixent surpassed €5 billion in quarterly sales, supporting positive sentiment amid pipeline adjustments under new CEO Belen Garijo.
SNY presents a mixed outlook with solid fundamentals and recent earnings beats offset by pipeline setbacks and competitive risks. The stock's valuation metrics, including a P/E of 23.38 and P/S of 1.88, appear reasonable relative to peers. However, investors face risks from biosimilar threats to Dupixent post-2031 and regulatory scrutiny. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism for upside potential driven by execution on new drug launches and cost discipline.
Walmart (WMT) trades at $115.72, up 2.17% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals, including consistent earnings beats, revenue growth to $681.0 billion in 2025, and a net income margin of 3.13%. Recent news highlights AI initiatives like Code Puppy and drone delivery expansion, supporting operational efficiency.
Outlook is positive with a $142.00 consensus price target, though risks include competitive pressure from Amazon and margin pressures. The stock offers growth potential from e-commerce and cost-saving tech, but investors should monitor execution against guidance and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
